Drug Trial Radar · NCT07042594
Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Aug 26, 2025
Primary completion
Aug 5, 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Suzhou Ribo Life Science Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants.
Conditions
- Healthy Volunteers
Interventions
RBD1119Drug
Subcutaneously Administered RBD1119 in Healthy Subjects.
PlaceboDrug
Subcutaneously Administered Placebo in Healthy Subject.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0Time frame: Up to Day 85
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.